# Roberta Palla

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1838653/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 62 papers | 2,697 citations | 201385 27 h-index | 182168 51 g-index |
| 64 all docs | 64 docs citations | 64 times ranked | 2230 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. British Journal of Haematology, 2021, 192, 621-625. | 1.2 | 1 |
| 2 | Hemostatic alterations in COVID-19. Haematologica, 2021, 106, 1472-1475. | 1.7 | 34 |
| 3 | Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A. Haemophilia, 2021, 27, e441-e449. | 1.0 | 1 |
| 4 | Factor VIII Epitope Analysis Using a Random Peptide Phage-Display Library Approach in the Sippet Cohort. Blood, 2021, 138, 3176-3176. | 0.6 | 0 |
| 5 | Clinical and laboratory diagnosis of rare coagulation disorders (RCDs). Thrombosis Research, 2020, 196, 603-608. | 0.8 | 9 |
| 6 | An international registry of patients with plasminogen deficiency (HISTORY). Haematologica, 2020, 105, 554-561. | 1.7 | 13 |
| 7 | Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopenic Purpura: Fourteen Years of the Milan TTP Registry. Thrombosis and Haemostasis, 2019, 119, 695-704. | 1.8 | 41 |
| 8 | Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A. Haematologica, 2019, 104, e369-e372. | 1.7 | 4 |
| 9 | Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis". Blood Transfusion, 2019, 17, 86. | 0.3 | 0 |
| 10 | Timing and severity of inhibitor development in recombinant versus plasmaâ€derived factor VIII concentrates: a SIPPET analysis. Journal of Thrombosis and Haemostasis, 2018, 16, 39-43. | 1.9 | 39 |
| 11 | Risk factors for inhibitor development in severe hemophilia A. Thrombosis Research, 2018, 168, 20-27. | 0.8 | 67 |
| 12 | Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 1887-1890. | 1.9 | 98 |
| 13 | Choices of factor <scp>VIII</scp> products in previously untreated patients with haemophilia A: A global survey. Haemophilia, 2018, 24, e266-e268. | 1.0 | 0 |
| 14 | High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis. Blood Transfusion, 2018, 16, 215-220. | 0.3 | 12 |
| 15 | Detection of Factor XIII deficiency: data from multicentre exercises amongst UK NEQAS and PRO-RBDD project laboratories. International Journal of Laboratory Hematology, 2017, 39, 350-358. | 0.7 | 6 |
| 16 | SIPPET: methodology, analysis and generalizability. Haemophilia, 2017, 23, 353-361. | 1.0 | 27 |
| 17 | Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. Blood, 2017, 129, 1245-1250. | 0.6 | 41 |
| 18 | Minimal factor XIII activity level to prevent major spontaneous bleeds. Journal of Thrombosis and Haemostasis, 2017, 15, 1728-1736. | 1.9 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Potential misdiagnosis of dysfibrinogenaemia: Data from multicentre studies amongst UK NEQAS and PROâ€RBDD project laboratories. International Journal of Laboratory Hematology, 2017, 39, 653-662. | 0.7 | 13 |
| 20 | Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. Blood, 2017, 130, 1757-1759. | 0.6 | 44 |
| 21 | Establishment of a bleeding score as a diagnostic tool for patients with rare bleeding disorders. Thrombosis Research, 2016, 148, 128-134. | 0.8 | 22 |
| 22 | Genetic Risk Stratification to Minimize Inhibitor Risk with the Use of Recombinant Factor VIII Concentrates: A Sippet Analysis. Blood, 2016, 128, 325-325. | 0.6 | 1 |
| 23 | Risk Differential in Inhibitor Development in the First Days of Treatment By Product Class: A Sippet Analysis. Blood, 2016, 128, 330-330. | 0.6 | 0 |
| 24 | Prospective Evaluation of Bleeding Incidence in Fibrinogen Deficiency (PRO-RBDD Study). Blood, 2016, 128, 207-207. | 0.6 | 0 |
| 25 | Rare bleeding disorders: diagnosis and treatment. Blood, 2015, 125, 2052-2061. | 0.6 | 244 |
| 26 | FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients. Thrombosis and Haemostasis, 2014, 112, 297-303. | 1.8 | 19 |
| 27 | A recurrent Gly43Asp substitution in coagulation Factor X rigidifies its catalytic pocket and impairs catalytic activity and intracellular trafficking. Thrombosis Research, 2014, 133, 481-487. | 0.8 | 8 |
| 28 | Congenital thrombotic thrombocytopenic purpura with novel mutations in three unrelated turkish children. Pediatric Blood and Cancer, 2014, 61, 558-561. | 0.8 | 4 |
| 29 | Rare Bleeding Disorders: Worldwide Efforts for Classification, Diagnosis, and Management. Seminars in Thrombosis and Hemostasis, 2013, 39, 579-584. | 1.5 | 58 |
| 30 | Diagnostic relevance of ADAMTS13 activity: Evaluation of 28 patients with thrombotic thrombocytopenic purpura - hemolytic uremic syndrome clinical diagnosis. Srpski Arhiv Za Celokupno Lekarstvo, 2013, 141, 466-474. | 0.1 | 0 |
| 31 | ADAMTSâ€13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2012, 10, 1556-1565. | 1.9 | 74 |
| 32 | The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 2322-2325. | 0.7 | 37 |
| 33 | Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. Journal of Thrombosis and Haemostasis, 2012, 10, 615-621. | 1.9 | 362 |
| 34 | Measurement of antiâ€ADAMTS13 neutralizing autoantibodies: a comparison between CBA and FRET assays. Journal of Thrombosis and Haemostasis, 2012, 10, 1439-1442. | 1.9 | 16 |
| 35 | B and T lymphocytes in acquired Thrombotic Thrombocytopenic Purpura during disease remission. Thrombosis Research, 2011, 128, 590-592. | 0.8 | 5 |
| 36 | Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies. Thrombosis and Haemostasis, 2011, 105, 381-385. | 1.8 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica, 2010, 95, 1444-1447. | 1.7 | 19 |
| 38 | Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. Free Radical Biology and Medicine, 2010, 48, 446-456. | 1.3 | 56 |
| 39 | ADAMTS13mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Human Mutation, 2010, 31, 11-19. | 1.1 | 165 |
| 40 | ADAMTS-13 assays in thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2010, 8, 631-640. | 1.9 | 103 |
| 41 | Active plateletâ€binding conformation of plasma von Willebrand factor in young women with acute myocardial infarction. Journal of Thrombosis and Haemostasis, 2010, 8, 1653-1656. | 1.9 | 19 |
| 42 | Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2010, 8, 2053-2062. | 1.9 | 31 |
| 43 | Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. British Journal of Haematology, 2010, 151, 488-494. | 1.2 | 46 |
| 44 | The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura. Haematologica, 2009, 94, 289-293. | 1.7 | 22 |
| 45 | Introduction: Rare Bleeding Disorders: General Aspects of Clinical Features, Diagnosis, and Management. Seminars in Thrombosis and Hemostasis, 2009, 35, 349-355. | 1.5 | 123 |
| 46 | Fibrinogen concentrates. Clinical Advances in Hematology and Oncology, 2009, 7, 788-90. | 0.3 | 5 |
| 47 | Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). Journal of Thrombosis and Haemostasis, 2008, 6, 1534-1541. | 1.9 | 57 |
| 48 | Mechanistic Studies on ADAMTS13 Catalysis. Biophysical Journal, 2008, 95, 2450-2461. | 0.2 | 22 |
| 49 | ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica, 2008, 93, 232-239. | 1.7 | 250 |
| 50 | DETERMINATION OF ANTI-ADAMTS13 AUTOANTIBODIES IN THROMBOTIC TROMBOCITOPENIC PURPURA (TTP) PATIENTS: COMPARISON OF TWO DIFFERENT METHODS. Journal of Thrombosis and Haemostasis, 2007, 5, P-T-303-P-T-303. | 1.9 | 2 |
| 51 | Thrombospondin-1 as a Modulator of ADAMTS13 Activity.. Blood, 2007, 110, 3711-3711. | 0.6 | 0 |
| 52 | The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. Blood, 2006, 108, 1280-1283. | 0.6 | 52 |
| 53 | The natural mutation by deletion of Lys9 in the thrombin A-chain affects the pKa value of catalytic residues, the overall enzyme's stability and conformational transitions linked to Na+ binding. FEBS Journal, 2006, 273, 159-169. | 2.2 | 30 |
| 54 | Genetic diagnosis of haemophilia and other inherited bleeding disorders. Haemophilia, 2006, 12, 82-89. | 1.0 | 123 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Rare bleeding disorders. Haemophilia, 2006, 12, 137-142. | 1.0 | 76 |
| 56 | Mechanisms of the interaction between twoADAMTS13 gene mutations leading to severe deficiency of enzymatic activity. Human Mutation, 2006, 27, 330-336. | 1.1 | 39 |
| 57 | Molecular Mapping of the Chloride-binding Site in von Willebrand Factor (VWF). Journal of Biological Chemistry, 2006, 281, 30400-30411. | 1.6 | 17 |
| 58 | Role of the 2 adenine (g.11293_11294insAA) insertion polymorphism in the 3â€² untranslated region of the factor VII (FVII) gene: molecular characterization of a patient with severe FVII deficiency. Human Mutation, 2005, 26, 455-461. | 1.1 | 16 |
| 59 | Role of Chloride Ions in Modulation of the Interaction between von Willebrand Factor and ADAMTS-13. Journal of Biological Chemistry, 2005, 280, 23295-23302. | 1.6 | 43 |
| 60 | Localization and Function of Platelet ADAMTS-13.. Blood, 2005, 106, 3967-3967. | 0.6 | 0 |
| 61 | The P303T mutation in the human factor VII (FVII) gene alters the conformational state of the enzyme and causes a severe functional deficiency. British Journal of Haematology, 2004, 127, 576-584. | 1.2 | 5 |
| 62 | Pitfalls in molecular diagnosis in a family with severe factor VII (FVII) deficiency?misdiagnosis by direct sequence analysis using a PCR product. Prenatal Diagnosis, 2003, 23, 731-734. | 1.1 | 15 |